At a glance
ClinicalIndex Comparison RecordN/ACompleted· 673 enrolled
Drug / intervention
No interventiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Sep 25, 2008·Updated Feb 1, 2021
In Brief
An observational study evaluating No intervention for Optic Neuropathy, Ischemic. Completed, enrolled 673 participants across 105 sites in 6 countries.
Detailed Summary
The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOptic Neuropathy, Ischemic
CountriesFrance, Germany, Italy, Spain, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartNov 2008
Primary CompletionOct 2012
TodayJul 2026
First PostedSep 25, 2008
Enrollment StartNov 1, 2008
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 17.8 years ago
Interventions
No interventiondrug
No intervention occurs in this observational study.